( evidence thatdemonstrate that the add...)Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting,Health

evidence that demonstrate that the addition of Thalidomide to front-line melphalan/prednisone therapy represents a safe and effective treatment for even very elderly patients with multiple myeloma in Europe, where melphalan/prednisone (MP) is currently the standard of care.

Satraplatin, will be the subject of an oral presentation at the Conference. The oral presentation will discuss the progression-free survival results of the randomized Phase III SPARC study (Satraplatin and Prednisone Against Refractory Cancer) in hormone-refractory prostate cancer patients. In addition, Pharmion and GPC Biotech will co-sponsor a satellite symposium on the evening of Friday, June 1, titled "Emerging Strategies for the Management of Advanced Prostate Cancer."

Interim data on a Phase II study of Amrubicin appears in the ASCO 2007 conference publication, and will be discussed at Pharmion's Investor and Analyst Event to be held Monday, June 4, from 6:00 to 7:30pm in Chicago. The meeting will be webcast on the company's website.

The following clinical data will be presented in poster sessions (unless otherwise noted) during the ASCO 2007 annual meeting:

Vidaza(R)

Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine (Vidaza) in patients with MDS -- R. Lyons, US Oncology; Abstract #7083; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

An oral dosage formulation of azacitidine: A pilot pharmacokinetic study -- R. Ward, Pharmion; Abstract #7084; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

Response to azacitidine in patients with myelodysplastic syndrome with marrow fibrosis -- R. Juvvadi, Western Penn, Pennsylvania; Abstract #7089; June 2, 2007; 8:00am-12:00pm; McCormick Place Convention Center, S Hall A2

The combination of 5-azacytidine and valproic acid is safe and active in advanced solid tumors -- A.O. Soriano, MD Anders
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference